Clinical Phenotypes of DMD Exon 51 Skip Equivalent Deletions: A Systematic Review
{{output}}
Background: Eteplirsen, the first FDA-approved RNA-modifying therapy for DMD, is applicable to ∼13% of patients with DMD. Because multiple exonic deletions are amenable to exon 51 skipping, the isoforms resulting from the variou... ...
